Novolilly Pharmaceutical Private Limited, a active private limited company, was established on 08 June 2021 in Panchkula, Haryana, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24299HR2021PTC095493. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹0.10 M and a paid-up capital of ₹0.10 M.
Its leadership includes Vaneet Jain (Director), Navneet Bansal (Director), Gomeda Bansal (Additional Director). Past directors included Husandeep Bansal. It holds ₹5.10 M open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at House No.590,Sector 4 Urban Estate, Panchkula, Haryana, 134112.
U24299HR2021PTC095493
095493
08 June 2021
₹0.10 M
₹0.10 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Novolilly Pharmaceutical Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vaneet Jain | Director | 08 Jun 2021 | Current |
| Navneet Bansal | Director | 08 Jun 2021 | Current |
| Gomeda Bansal | Additional Director | 08 Jan 2022 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 08 Jan 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Novolilly Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 378.37% increase. The company also saw a substantial improvement in profitability, with a 60.78% increase in profit. The company's net worth observed a substantial decline by a decrease of 42.41%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
Unlock access to Novolilly Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Reveal ownership structures and financial performance - Get instant access now!
₹5,100,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Dec 2024 | Axis Bank Limited | ₹5.10 M | Open |
Explore comprehensive loan charge details -
Novolilly Pharmaceutical has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Novolilly Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novolilly Pharmaceutical's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
A charge with Axis Bank Limited amounted to Rs. 5.10 M with Charge ID 101018776 was registered on 06 Dec 2024. was recorded as a recent event.
The activity Novolilly Pharmaceutical Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Novolilly Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was recorded as a recent event.
Progress on Gomeda Bansal was appointed as a Additional Director was appointed as a Additional Director on 08 Jan 2022 & has been associated with this company since 3 years 10 months . was documented.
Progress on Vaneet Jain was appointed as a Director was appointed as a Director on 08 Jun 2021 & has been associated with this company since 4 years 5 months . was documented.
Progress on Navneet Bansal was appointed as a Director was appointed as a Director on 08 Jun 2021 & has been associated with this company since 4 years 5 months . was documented.
The CIN of Novolilly Pharmaceutical Private Limited is U24299HR2021PTC095493.
Novolilly Pharmaceutical Private Limited is headquartered at House No.590,Sector 4 Urban Estate, Panchkula, Haryana, 134112.
Novolilly Pharmaceutical Private Limited was incorporated on 08 June 2021.
The current directors of Novolilly Pharmaceutical Private Limited are
The primary industry of Novolilly Pharmaceutical Private Limited is Manufacturing.
Novolilly Pharmaceutical Private Limited is unlisted.
The authorized capital of Novolilly Pharmaceutical Private Limited is ₹0.10 M, and the paid-up capital is ₹0.10 M.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX